DLL3-targeted immunotherapies present promising opportunities in treating small cell lung cancer (SCLC) and neuroendocrine carcinomas (NECs) due to DLL3's high expression in these tumors and minimal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback